HANTECH BIO-TECH (1294), a major contract manufacturer specializing in filling services for retort pouch health beverages, is expected to list on the Taipei Exchange (TPEx) in late September. HANTECH Chairman Lee Yu-Lin said that production capacity is already in place and the company will accelerate the development of both domestic and overseas markets.
HANTECH BIO-TECH was founded in 2007 and initially focused on the sale of traditional Chinese medicinal ingredients, particularly Guilu-related materials. In 2010, the company began developing low-temperature grinding technology for ultra-fine nano pearl powder. In 2012, it introduced horizontal filling machines and sterilization equipment for retort pouches and expanded into health supplement filling and contract manufacturing services. Its current core businesses include the R&D, ODM, and OEM manufacturing of liquid and crystal-jelly health supplements, providing one-stop contract manufacturing services covering everything from formulation design to retort pouch filling and packaging.
Lee said that growing consumer awareness of health and wellness in the post-pandemic era has continued to drive growth in the health supplement market. HANTECH BIO-TECH’s liquid retort pouches are significantly less expensive than traditional glass bottles, while also being compact and easy to transport. Many brand customers have gradually switched their product packaging to retort pouches manufactured by HANTECH, driving strong growth in demand for retort pouch beverage packaging.
HANTECH’s Yuanlin plant produced more than 80 million pouches last year. This year, the Xihu Headquarters facility officially began operations, with monthly production capacity reaching 18 million pouches. Going forward, the Yuanlin plant will focus on the filling and packaging of jelly products, while liquid products will be transferred to the Xihu facility for filling and production.
Lee said that HANTECH’s sales are currently concentrated mainly in Taiwan. However, due to the limited size of the Taiwan market, the company has recently accelerated its development of overseas markets. It has already expanded its customer base to Hong Kong, Malaysia, Singapore, and China. The continued expansion of new customers, new products, and new sales regions is expected to provide additional growth momentum for the company.
HANTECH BIO-TECH reported revenue of NTD 625 million last year, representing year-over-year growth of 106.65%. Net profit after tax reached NTD 148 million, while earnings per share (EPS) stood at NTD 7.66. Revenue for the first seven months of this year reached NTD 474 million, up 56.20% year over year. The company has maintained strong growth for three consecutive years.
Source:
News Source: https://ec.ltn.com.tw/article/breakingnews/4781700
